Antibe Therapeutics Inc.
ATBPF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,303 | $3,430 | $3,567 | $1,575 |
| G&A Expenses | $2,212 | $1,923 | $2,566 | $2,135 |
| SG&A Expenses | $2,293 | $2,019 | $2,713 | $2,191 |
| Sales & Mktg Exp. | $81 | $96 | $147 | $56 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,596 | $5,449 | $6,280 | $3,582 |
| Operating Income | -$4,596 | -$5,449 | -$6,280 | -$3,582 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $383 | $443 | $494 | $346 |
| Pre-Tax Income | -$4,213 | -$5,006 | -$5,786 | -$3,236 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,213 | -$5,006 | -$5,786 | -$3,548 |
| % Margin | – | – | – | – |
| EPS | -0.08 | -0.1 | -0.11 | -0.067 |
| % Growth | 20% | 9.1% | -63.2% | – |
| EPS Diluted | -0.08 | -0.1 | -0.11 | -0.067 |
| Weighted Avg Shares Out | 52,651 | 52,637 | 52,630 | 52,617 |
| Weighted Avg Shares Out Dil | 52,651 | 52,637 | 52,630 | 52,617 |
| Supplemental Information | – | – | – | – |
| Interest Income | $388 | $464 | $484 | $355 |
| Interest Expense | $2 | $2 | $2 | $2 |
| Depreciation & Amortization | $0 | -$80 | $416 | $25 |
| EBITDA | -$4,211 | -$5,004 | -$5,368 | -$3,227 |
| % Margin | – | – | – | – |